Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | SLC40A1 | Q9NP59 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.32 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4893741 | 0.91 | KMT2A (0.41) | ALDH1A1SLC40A1HPGDMEN1KMT2A | |
| SCHEMBL4892890 | 0.88 | MMP2 (0.39) | MMP2ALDH1A1SLC40A1HPGDMEN1 | |
| SCHEMBL4772779 | 0.86 | ADRB3 (0.44) | MMP2HPGDNR1I2 | |
| SCHEMBL4773343 | 0.86 | ADRB3 (0.44) | MMP2HPGDNR1I2 | |
| SCHEMBL4889589 | 0.86 | ADRB3 (0.44) | MMP2HPGDNR1I2 | |
| SCHEMBL4894151 | 0.86 | HPGD (0.35) | MMP2ALDH1A1SLC40A1HPGDMEN1 | |
| SCHEMBL4896292 | 0.86 | HPGD (0.37) | MMP2ALDH1A1HPGDMEN1CRHBP | |
| SCHEMBL4915383 | 0.85 | FGFR1 (0.36) | ALDH1A1HPGDMEN1CRHBPKMT2A | |
| SCHEMBL4914673 | 0.84 | CCR2 (0.34) | ALDH1A1MEN1KMT2ANR1I2 | |
| SCHEMBL2201475 | 0.83 | NR1I2 (0.40) | ALDH1A1HPGDKMT2ASLC16A3NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269281-A1 | Novel Beta-Agonists, Method for Producing Them and Their Use as Drugs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-30 | — | — | US | claimed |
| US-20080269281-A1 | Novel Beta-Agonists, Method for Producing Them and Their Use as Drugs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269281-A1 | Novel Beta-Agonists, Method for Producing Them and Their Use as Drugs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269281-A1 | Novel Beta-Agonists, Method for Producing Them and Their Use as Drugs | ADRB3, ADRB2, ADRB1 | MMP2 3236/4885ALDH1A1 1087/4885MAPK14 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.